Navigation Links
Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually

April is STD Awareness Month: Time to Pay Attention to this Overlooked Disease

SAN ANTONIO, Texas, April 02, 2007 /PRNewswire/ -- During National Sexually Transmitted Disease (STD) Awareness Month this April, Mission Pharmacal is urging increased awareness of, and testing for, trichomoniasis (also known as "trich"), the most common curable STD in the United States. Awareness of the condition remains low, despite the fact that trich affects an estimated 7.4 million men and women each year in the United States, compared with 3 million cases of chlamydia and 700,000 cases of gonorrhea annually.

If left untreated, trich can lead to more serious health problems in both men and women, including increasing the likelihood of HIV acquisition and transmission. In women, untreated trich may contribute to an increased risk of infertility, cervical cancer, pelvic inflammatory disease, preterm birth and postoperative infection. The consequences of untreated trich in men include decreased sperm count and movement, increased risk of infertility, and chronic pain in the prostate or pelvic region.

Because trich is generally asymptomatic or only mildly symptomatic, people often don't know they are infected. This lack of awareness often leads to a delay in seeking treatment, thereby increasing the likelihood that the untreated infection will be passed on to others. A recent study of trich- infected women found that more than 71 percent of their male partners were also infected, although most of the men did not show symptoms (1).

"Despite its prevalence and the consequences of leaving it untreated, routine testing is not being conducted for trichomoniasis," stated Dr. Jane Schwebke, professor of infectious diseases at the University of Alabama at Birmingham. "Because patients may not experience symptoms when infected, healthcare providers need to be vigilant about testing sexually active patients, and patients should request testing if they suspect they are at risk."

Fortunately, trich can be cured with a one-day, one-dose regimen of Tindamax(R) (tinidazole). Tindamax(R) is administered orally in a single 2- gram dose, and has demonstrated cure rates of 92 to 100 percent. In addition, Tindamax(R) is recognized as one of the drugs of choice for the treatment of trichomoniasis in the recently issued 2006 Sexually Transmitted Diseases Treatment Guidelines (www.cdc.gov/std/treatment) from the Centers for Disease Control and Prevention (CDC).

Sexual partners should be treated simultaneously for maximum efficacy and prevention of re-infection. More information on Tindamax(R) and trichomoniasis is available at http://www.tindamax.com.

About Tindamax(R)

Tindamax(R), a second-generation 5-nitroimidazole compound, is indicated in the United States for the treatment of trichomoniasis, the intestinal infections giardiasis and intestinal amebiasis, and amebic liver abscess. It has been approved for use in the United States since May 2004 and is recognized as one of the drugs of choice for the treatment of trichomoniasis by the Centers for Disease Control and Prevention (CDC).

Full prescribing information for Tindamax(R), as well as information about trichomoniasis, is available at http://www.tindamax.com.

About Mission Pharmacal

Mission Pharmacal, the maker of Citracal(R), is a family-owned pharmaceutical company based in San Antonio, Texas. For more than 60 years, the company has been dedicated to identifying unmet health needs in the marketplace and developing innovative prescription and over-the-counter products to meet them. Currently, Mission Pharmacal provides physicians and consumers with pharmaceutical, nutritional and diagnostic products. For more informa tion, visit http://missionpharmacal.com.

(1) A.C. Sena, W.C. Miller, M.M. Hobbs, J.R. Schwebke, P.A. Leone, H. Swygard, J. Atashili, and M. Cohen. Trichomoniasis vaginalis Infection in Male Sexual Partners: Implications for Diagnosis, Treatment, and Prevention. Clinical Infections Diseases 2007; 44: 13-22.

CONTACT: Alicia Samuels of GCI Group, +1-212-537-8170,, for Mission Pharmacal asamuels@gcigroup.com

Web site: http://missionpharmacal.com/http://www.tindamax.com/http://www.cdc.gov/std/treatment/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
4. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
5. Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer
6. One-Third of Patients Discontinue Common Breast Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 On Friday, benchmark ... Composite closed the trading session up 0.19%; the Dow ... 500 was down 0.08%. US markets made broad based ... day in green. Pre-market today, Stock-Callers.com reviews these four ... (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. (NASDAQ: ... Paul M. Bisaro as Impax,s President and ... Board, effective March 27, 2017. Mr. Bisaro will succeed ... Interim President and Chief Executive Officer since December of ... and branded pharmaceutical experience, Mr. Bisaro, 56, is an ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... sideline athletes. A type of groin injury, it occurs when the muscles around ... intense pain in and around the lower torso, as well as accompanying tenderness ...
(Date:3/27/2017)... ... 2017 , ... EpiGentek , a Farmingdale, NY-based biotech ... methylation “gold rush” with their established portfolio of optimized assay kits that measure ... m6A , RNA methylation has received a new burst in interest as ...
(Date:3/27/2017)... ... March 27, 2017 , ... Janet Schloz is still in shock after receiving a $2,500 Academic ... in a long time,” she said. , She thinks the coming week is going to ... thought I would have to help my students.” , The award will allow the 4th ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... sodium testing methods are complicated and require expert user knowledge. In a live ... method dedicated to the simplified, yet highly accurate, determination of sodium. , It ...
(Date:3/27/2017)... Orange, Texas (PRWEB) , ... March 27, 2017 ... ... celebration at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to ... giveaways and will be an opportunity for area-residents to celebrate two great years ...
Breaking Medicine News(10 mins):